

Anti-hBCMA-βGal

Bispecific antibody against human BCMA and β-galactosidase; Negative control

Catalog code: bimab-bcmabg-01, bimab-bcmabg-05

<https://www.invivogen.com/anti-human-bcma-bgal>

For research use only, not for diagnostic or therapeutic use

Version 24D02-AK

PRODUCT INFORMATION

Contents: Anti-hBCMA-βGal purified monoclonal antibody (mAb) is provided azide-free and lyophilized. It is available in two quantities:

bimab-bcmabg-01: 10 μg

bimab-bcmabg-05: 5 x 10 μg

Target: Human B cell maturation antigen (hBCMA) and *E. coli* β-galactosidase (β-Gal)

Specificity: Cells expressing *E. coli* β-galactosidase (β-Gal) and hBCMA

Clonality: Monoclonal antibody

Source: Chinese hamster ovary (CHO) cells

Formulation: Anti-hBCMA-βGal is lyophilized from a 0.2 μm filtered phosphate buffer solution (pH 7.4) containing 5% saccharose.

Purity: > 90%. Purified by affinity chromatography

Storage and stability

- Product is shipped at room temperature. Upon receipt, store at -20°C.
- Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

Quality control

- Binding of Anti-hBCMA-βGal to hBCMA has been confirmed by flow cytometry.
- The inability of Anti-hBCMA-βGal to bind to hCD3 has been confirmed using ELISA.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

METHODS

Anti-hBCMA-βGal resuspension (100 μg/ml)

Note: Ensure you see the lyophilized pellet before resuspension.

- Add 100 μl of sterile water to the vial and gently pipet until completely resuspended.
- Prepare aliquots and store at -20°C until required.

RESTRICTION USE

This antibody is distributed for research purposes only. It is not intended for diagnosis or therapeutic use.




Figure 1. Anti-hBCMA-βGal still binds to hBCMA on cancer cells, but not to hCD3 on T cells.

DESCRIPTION

Anti-hBCMA-βGal is a bispecific antibody that binds to two sites: human B cell maturation antigen (hBCMA) and *E. coli* β-galactosidase (βGal). It is used as a negative control for the Anti-hBCMA-CD3 bispecific antibody that, unlike pacanalotamab, engages unstimulated T cells to proliferate and exert cytotoxic activity on BCMA-positive myeloma cells¹ (Figure 1).

BACKGROUND

The human BCMA (also known as CD269 or TNFRSF17) is a type III transmembrane glycoprotein playing a central role in B cell maturation and differentiation towards plasma cells². It is expressed on plasma cells, mature B cells as well as multiple myeloma cells. By interacting with its ligands, hBCMA activates several pathways promoting B cell survival and proliferation, but also tumor cell growth and drug resistance²⁻³.

1. **Topp et al., 2020.** Anti-B-Cell Maturation Antigen BITE Molecule AMG 420 Induces Responses in Multiple Myeloma. *J Clin Oncol.* 2020 Mar 10;38(8):775-783. 2. **Hosny et al., 2021.** Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. *J Clin Med.* Oct 6;10(19):4593. 3. **Abramson et al., 2020.** B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. *Int J Mol Sci.* 2020;21(15):5192.

RELATED PRODUCTS

Product	Cat. Code
Anti-hBCMA-CD3	bimab-bcmacd3-05

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3622-3480

E-mail: info@invivogen.com